Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis

被引：0
|
作者：
Tribich, Samuel
Maurice, James
机构：
来源：
FRONTLINE GASTROENTEROLOGY | 2020年 / 11卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Vedolizumab Combined with Upadacitinib in Moderate-to-Severe Ulcerative Colitis: A Multicenter, Prospective, Randomized Controlled Trial
    Wu, H.
    Su, T.
    Wu, L.
    Zhi, M.
    Yao, J.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i195 - i197
  • [32] Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Colombel, Jean-Frederic
    Danese, Silvio
    Rogers, Raquel
    Bornstein, Jeffrey D.
    Chen, Jingjing
    Schreiber, Stefan
    Sands, Bruce E.
    Lirio, Richard A.
    GASTROENTEROLOGY, 2021, 161 (04) : 1156 - +
  • [33] Adalimumab Versus Infliximab in Inducing Mucosal Healing in Moderate-to-Severe Ulcerative Colitis: A Cost-Per-Remission Decision Analytic Study
    Park, K. T.
    Yokomizo, L.
    GASTROENTEROLOGY, 2015, 148 (04) : S199 - S199
  • [34] SYSTEMATIC REVIEW AND META-ANALYSIS OF INFLIXIMAB, ADALIMUMAB, GOLIMUMAB, VEDOLIZUMAB, AND TOFACITINIB FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS IN ANTI-TNF-ALPHA-NAIVE PATIENTS
    Takahashi, S.
    Yamabe, K.
    VALUE IN HEALTH, 2020, 23 : S143 - S143
  • [35] Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
    Petryszyn, Pawel
    Ekk-Cierniakowski, Pawel
    Zurakowski, Grzegorz
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [36] COST-EFFECTIVENESS OF GOLIMUMAB VERSUS INFLIXIMAB AND ADALIMUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS
    Thorlund, K.
    Druyts, E.
    Eapen, S.
    Mills, E.
    VALUE IN HEALTH, 2014, 17 (03) : A38 - A38
  • [37] Systematic Review and Meta-Analysis Comparing Adalimumab and Vedolizumab in Treating Moderate to Severe Ulcerative Colitis: Effectiveness and Safety
    Merza, Nooraldin
    Ahmed, Zohaib
    Nawras, Mohamad
    Dahiya, Dushyant Singh
    Merza, Fatima
    Merza, Fatima A.
    Boujemaa, Safa
    Naguib, Tarek
    Hassan, Mona
    Islam, Asm
    Kobeissy, Abdallah A.
    Alastal, Yaseen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S706 - S707
  • [38] COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH INFLIXIMAB, ADALIMUMAB, GOLIMUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS IN GERMANY
    Quon, P.
    Sardesai, A.
    Milev, S.
    DiBonaventura, M.
    Cappelleri, J. C.
    Kisser, A.
    Modesto, I
    Dietz, L.
    Dignass, A.
    Bargo, D.
    VALUE IN HEALTH, 2019, 22 : S617 - S617
  • [39] Cost-Effectiveness of Golimumab Versus Infliximab and Adalimumab for the Treatment of Moderate to Severe Ulcerative Colitis
    Druyts, Kristian Thorlund Eric
    Kanters, Steve
    Eapen, Shawn
    Mills, Edward
    GASTROENTEROLOGY, 2014, 146 (05) : S202 - S202
  • [40] Are We Ready for Combination Therapy in Moderate-to-Severe Ulcerative Colitis?
    Lee, Yeong Yeh
    Gangireddy, Venugopalareddy
    Khurana, Sandeep
    Rao, Satish S. C.
    GASTROENTEROLOGY, 2014, 147 (02) : 544 - 544
12345